EE41 Cost-Utility of Nivolumab Versus Observation for the Adjuvant Treatment of Urothelial Carcinoma (UC) for Patients Who Are at High-Risk of Recurrence: A Canada Public Payer Perspective
Value in health（2023）
摘要
To estimate the cost-utility of adjuvant UC treatment with nivolumab versus observation after radical resection from a Canadian public-payer perspective.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要